Plasma D-dimer and prothrombin fragment 1+2 in evaluating the occurrence of venous thromboembolism in advanced cancer patients and the effect of preventive anticoagulant therapy.
{"title":"Plasma D-dimer and prothrombin fragment 1+2 in evaluating the occurrence of venous thromboembolism in advanced cancer patients and the effect of preventive anticoagulant therapy.","authors":"Yongliang Huang, Yongchun Xu, Chuanqing Ke, Baiping Zhang, Ying Zhong, Huiying Fu","doi":"10.5937/jomb0-55897","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>This study aimed to evaluate the role of D-dimer (DD) and prothrombin fragment 1+2 (PF1+2) in assessing the risk of venous thromboembolism (VTE) in advanced cancer patients, as well as the impact of preventive anticoagulant therapy.</p><p><strong>Methods: </strong>A total of 137 advanced cancer patients admitted to the 908th Hospital of the Chinese People's Liberation Army Joint Logistic Support Force Hospital between February 2023 and June 2024 were included. Patients were divided into two groups based on the presence (VTE group, n=49) or absence (non-VTE group, n=88) of VTE. Blood tests were performed at admission, and the relationship between DD, PF1+2, and VTE risk was analysed. Patients without VTE were further categorised into two treatment groups: the preventive anticoagulant treatment group (AG, n=48) and the conventional treatment group (RT, n=40), based on their preference. The incidence of VTE in both groups was compared to assess the effectiveness of preventive anticoagulant therapy.</p><p><strong>Results: </strong>Before chemotherapy, DD levels were significantly higher in patients who developed VTE than those who did not. Both DD and PF1+2 were found to be independent risk factors for VTE after chemotherapy. The incidence of VTE was lower in the AG group than in the RT group, with a statistically significant difference.</p><p><strong>Conclusions: </strong>DD and PF1+2 are reliable indicators for assessing VTE risk in advanced cancer patients and can help guide the use of preventive anticoagulant therapy.</p>","PeriodicalId":16175,"journal":{"name":"Journal of Medical Biochemistry","volume":"44 6","pages":"1305-1313"},"PeriodicalIF":1.5000,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12499894/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medical Biochemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5937/jomb0-55897","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: This study aimed to evaluate the role of D-dimer (DD) and prothrombin fragment 1+2 (PF1+2) in assessing the risk of venous thromboembolism (VTE) in advanced cancer patients, as well as the impact of preventive anticoagulant therapy.
Methods: A total of 137 advanced cancer patients admitted to the 908th Hospital of the Chinese People's Liberation Army Joint Logistic Support Force Hospital between February 2023 and June 2024 were included. Patients were divided into two groups based on the presence (VTE group, n=49) or absence (non-VTE group, n=88) of VTE. Blood tests were performed at admission, and the relationship between DD, PF1+2, and VTE risk was analysed. Patients without VTE were further categorised into two treatment groups: the preventive anticoagulant treatment group (AG, n=48) and the conventional treatment group (RT, n=40), based on their preference. The incidence of VTE in both groups was compared to assess the effectiveness of preventive anticoagulant therapy.
Results: Before chemotherapy, DD levels were significantly higher in patients who developed VTE than those who did not. Both DD and PF1+2 were found to be independent risk factors for VTE after chemotherapy. The incidence of VTE was lower in the AG group than in the RT group, with a statistically significant difference.
Conclusions: DD and PF1+2 are reliable indicators for assessing VTE risk in advanced cancer patients and can help guide the use of preventive anticoagulant therapy.
期刊介绍：
The JOURNAL OF MEDICAL BIOCHEMISTRY (J MED BIOCHEM) is the official journal of the Society of Medical Biochemists of Serbia with international peer-review. Papers are independently reviewed by at least two reviewers selected by the Editors as Blind Peer Reviews. The Journal of Medical Biochemistry is published quarterly.
The Journal publishes original scientific and specialized articles on all aspects of
clinical and medical biochemistry,
molecular medicine,
clinical hematology and coagulation,
clinical immunology and autoimmunity,
clinical microbiology,
virology,
clinical genomics and molecular biology,
genetic epidemiology,
drug measurement,
evaluation of diagnostic markers,
new reagents and laboratory equipment,
reference materials and methods,
reference values,
laboratory organization,
automation,
quality control,
clinical metrology,
all related scientific disciplines where chemistry, biochemistry, molecular biology and immunochemistry deal with the study of normal and pathologic processes in human beings.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
